Remission rates with 3 consecutive antidepressant trials: Effectiveness for depressed outpatients

Journal of Clinical Psychiatry

Volumn 66, Issue 6, 2005, Pages 670-676

  Quitkin, Frederic M ^a,b   McGrath, Patrick J ^a   Stewart, Jonathan W ^a   Deliyannides, Deborah ^a   Taylor, Bonnie P ^a   Davies, Carrie A ^a   Klein, Donald F ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; GEPIRONE; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; PHENELZINE; PLACEBO; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GOOD CLINICAL PRACTICE; HAMILTON SCALE; HUMAN; INTENT TO TREAT ANALYSIS; MAJOR DEPRESSION; OUTPATIENT; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 21744444611     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0601     Document Type: Article

References (24)

1. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston, Mass: The Harvard School of Public Health on behalf of The World Health Organization; 1996
2. Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
3. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA 2002;287:203-209
4. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-317
5. Rush AJ, Trivedi M, Fava M. Depression, 4: STAR*D treatment trial for depression. Am J Psychiatry 2003;160:237
6. Ormel J, Koeter MW, van den Brink W, et al. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991;48:700-706
7. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160: 1277-1285
8. Goode E. Antidepressants lift clouds, but lose 'miracle drug' label. New York Times. June 30, 2002:1.1
9. U.S. Food and Drug Administration. FDA Public Health Advisory: worsening depression and suicidality in patients being treated with antidepressant medications. Available at: http://www.fda.gov/cder/drug/ antidepressants/ AntidepressanstPHA.htm. Accessed April 6, 2004
10. Clinical Practice Guideline Number 5: Depression in Primary Care, 2: Treatment of Major Depression. Rockville, Md: Agency for Health Care Policy and Research, US Dept of Health and Human Services; 1993. AHCPR publication 93-0551
11. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(suppl 22):7-11
12. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
13. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. The treatment of chronic depression, pt 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998;59:598-607
14. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993;21:30-34
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
16. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale: preliminary report. Psychopharmacol Bull 1973;9:13-28
17. Dohrenwend BP, Shrout PE, Egri G, et al. Nonspecific psychological distress and other dimensions of psychopathology: measures for use in the general population. Arch Gen Psychiatry 1980;37:1229-1236
18. Bruder GE, Kayser J, Tenke CE, et al. Cognitive ERPs in depressive and anxiety disorders during tonal and phonetic oddball tasks. Clin Electroencephalogr 2002;33:119-124
19. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia (SADS), Third Edition. New York, NY: Biometric Research, New York State Psychiatric Institute; 1977
20. Endicott J, Cohen J, Nee J, et al. Hamilton Depression Rating Scale: extracted from regular and change versions of the Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 1981;38:98-103
21. Klein DF. Improvement of phase III psychotropic drug trials by intensive phase II work. Neuropsychopharmacology 1991;4:251-258
22. Quitkin FM, Rabkin JG, Gerald J, et al. Validity of clinical trials of antidepressants. Am J Psychiatry 2000;157:327-337
23. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-239
24. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097